X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2026-02-24 | VYGR | Voyager Therapeutics, Inc. | Swartz Robin | COO, CBO | S - Sale | $3.77 | -6,458 | 199,738 | -3% | -$24,347 | ||||||
2026-02-24 | VYGR | Voyager Therapeutics, Inc. | Sandrock Alfred | Pres, CEO | S - Sale | $3.79 | -14,197 | 484,060 | -3% | -$53,807 | ||||||
2026-02-24 | VYGR | Voyager Therapeutics, Inc. | Jorgensen Nathan D. | CFO | S - Sale | $3.77 | -4,668 | 151,416 | -3% | -$17,598 | ||||||
2026-02-24 | VYGR | Voyager Therapeutics, Inc. | Carter Todd Alfred | Chief Scientific Officer | S - Sale | $3.76 | -4,174 | 145,718 | -3% | -$15,694 | ||||||
2026-02-25 | ACLX | Arcellx, Inc. | Gilson Michelle | CFO | S - Sale | $113.82 | -11,219 | 33,938 | -25% | -$1,276,954 | ||||||
2026-02-23 | SRRK | Scholar Rock Holding Corp | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | S - Sale | $47.07 | -8,484 | 98,445 | -8% | -$399,351 | ||||||
| D | 2026-02-25 | KYMR | Kymera Therapeutics, Inc. | Mainolfi Nello | CEO | S - Sale+OE | $90.26 | -30,000 | 666,195 | -4% | -$2,707,813 | |||||
| M | 2026-02-23 | CGEM | Cullinan Therapeutics, Inc. | Michaelson Jennifer | Chief Scientific Officer | S - Sale | $14.31 | -5,353 | 176,624 | -3% | -$76,617 | |||||
2026-02-24 | CGEM | Cullinan Therapeutics, Inc. | Ahmed Nadim | Pres, CEO | S - Sale | $14.47 | -13,515 | 390,803 | -3% | -$195,562 | ||||||
2026-02-24 | CGEM | Cullinan Therapeutics, Inc. | Jones Jeffrey Alan | Chief Medical Officer | S - Sale | $14.47 | -4,582 | 159,968 | -3% | -$66,302 | ||||||
2026-02-24 | CGEM | Cullinan Therapeutics, Inc. | Sumer Jacquelyn L | GC | S - Sale | $14.47 | -3,601 | 128,089 | -3% | -$52,106 | ||||||
| D | 2026-02-23 | MRNA | Moderna, Inc. | Hoge Stephen | Pres | S - Sale+OE | $48.84 | -160,009 | 1,613,476 | -9% | -$7,814,840 | |||||
2026-02-23 | TWST | Twist Bioscience Corp | Finn Patrick John | Pres, COO | S - Sale | $46.71 | -4,294 | 284,129 | -1% | -$200,572 | ||||||
2026-02-23 | TWST | Twist Bioscience Corp | Werner Robert F. | Chief Accounting Officer | S - Sale | $46.71 | -1,693 | 55,045 | -3% | -$79,080 | ||||||
2026-02-23 | TWST | Twist Bioscience Corp | Laponis Adam | CFO | S - Sale | $46.71 | -2,085 | 128,291 | -2% | -$97,390 | ||||||
| D | 2026-02-23 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $46.71 | -7,205 | 863,052 | -1% | -$336,544 | |||||
2026-02-23 | TWST | Twist Bioscience Corp | Green Paula | SVP of HR | S - Sale | $46.71 | -1,465 | 125,336 | -1% | -$68,430 | ||||||
2026-02-23 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $46.71 | -844 | 138,682 | -1% | -$39,423 | ||||||
| D | 2026-02-24 | CRBU | Caribou Biosciences, Inc. | Kelly Timothy P | CTO | S - Sale+OE | $1.96 | -3,147 | 79,353 | -4% | -$6,168 | |||||
| D | 2026-02-24 | CRBU | Caribou Biosciences, Inc. | McClung Barbara G | GC | S - Sale+OE | $1.96 | -6,938 | 481,564 | -1% | -$13,598 | |||||
| D | 2026-02-24 | CRBU | Caribou Biosciences, Inc. | Khan Ruhi Ahmad | Chief Business Officer | S - Sale+OE | $1.96 | -6,938 | 104,998 | -6% | -$13,598 | |||||
| D | 2026-02-24 | CRBU | Caribou Biosciences, Inc. | Albertson Tina M. | Chief Medical Officer | S - Sale+OE | $1.96 | -1,066 | 68,523 | -2% | -$2,089 | |||||
| D | 2026-02-23 | IBRX | Immunitybio, Inc. | Selecky Christobel | Dir | S - Sale+OE | $10.00 | -25,000 | 0 | -100% | -$250,000 | |||||
| DM | 2026-02-20 | IBRX | Immunitybio, Inc. | Simon Barry J. | Dir | S - Sale+OE | $10.19 | -175,000 | 2,925,821 | -6% | -$1,783,602 | |||||
| D | 2026-02-23 | VIR | Vir Biotechnology, Inc. | Sabatini Brent | SVP, Chief Accounting Officer | S - Sale+OE | $7.45 | -1,829 | 71,043 | -3% | -$13,631 | |||||
| D | 2026-02-23 | VIR | Vir Biotechnology, Inc. | O'Byrne Jason | EVP, CFO | S - Sale+OE | $7.45 | -2,089 | 164,249 | -1% | -$15,569 | |||||
| D | 2026-02-23 | VIR | Vir Biotechnology, Inc. | Eisner Mark | EVP, Chief Medical Officer | S - Sale+OE | $7.45 | -2,089 | 157,529 | -1% | -$15,569 | |||||
| D | 2026-02-23 | VIR | Vir Biotechnology, Inc. | De Verneuil Vanina | EVP, GC, Corp Sec | S - Sale+OE | $7.45 | -4,445 | 129,799 | -3% | -$33,128 | |||||
| D | 2026-02-23 | VIR | Vir Biotechnology, Inc. | De Backer Marianne | CEO | S - Sale+OE | $7.45 | -19,039 | 1,088,584 | -2% | -$141,894 | |||||
| M | 2026-02-20 | ACOG | Alpha Cognition Inc. | Opaleye Management Inc. | 10% | P - Purchase | $5.86 | +171,410 | 2,364,410 | +8% | +$1,003,958 | |||||
| M | 2026-02-20 | TNYA | Tenaya Therapeutics, Inc. | Column Group III Gp, LP | 10% | S - Sale | $0.61 | -829,734 | 51,525,316 | -2% | -$504,787 | |||||
2026-02-23 | GLUE | Monte Rosa Therapeutics, Inc. | Janku Filip | Chief Medical Officer | S - Sale | $19.50 | -9,189 | 65,837 | -12% | -$179,161 | ||||||
| D | 2026-02-19 | KRYS | Krystal Biotech, Inc. | Rossi Dino A | Dir | S - Sale+OE | $261.41 | -18,950 | 78,691 | -19% | -$4,953,694 | |||||
2026-02-19 | EXEL | Exelixis, Inc. | Aftab Dana | EVP, Research, Development | S - Sale | $44.35 | -29,873 | 669,859 | -4% | -$1,324,868 | ||||||
2026-02-20 | CGEM | Cullinan Therapeutics, Inc. | Jones Jeffrey Alan | Chief Medical Officer | S - Sale | $13.62 | -4,982 | 164,550 | -3% | -$67,855 | ||||||
| D | 2026-02-20 | CGEM | Cullinan Therapeutics, Inc. | Michaelson Jennifer | Chief Scientific Officer | S - Sale+OE | $14.08 | -11,742 | 181,977 | -6% | -$165,366 | |||||
2026-02-20 | CGEM | Cullinan Therapeutics, Inc. | Sumer Jacquelyn L | GC | S - Sale | $13.62 | -3,742 | 131,690 | -3% | -$50,966 | ||||||
2026-02-20 | CGEM | Cullinan Therapeutics, Inc. | Ahmed Nadim | Pres, CEO | S - Sale | $13.62 | -16,381 | 404,318 | -4% | -$223,109 | ||||||
2026-02-20 | CGEM | Cullinan Therapeutics, Inc. | Fenton Mary Kay | CFO | S - Sale | $13.62 | -4,398 | 126,380 | -3% | -$59,901 | ||||||
| D | 2026-02-18 | EXEL | Exelixis, Inc. | Wyszomierski Jack L | Dir | S - Sale+OE | $44.01 | -99,574 | 279,942 | -26% | -$4,382,252 | |||||
2026-02-19 | AMGN | Amgen Inc | Busch Matthew C. | VP, Finance, CAO | S - Sale | $375.79 | -1,000 | 3,423 | -23% | -$375,790 | ||||||
| D | 2026-02-19 | CRSP | Crispr Therapeutics AG | Kulkarni Samarth | CEO | S - Sale+OE | $52.58 | -6,967 | 226,106 | -3% | -$366,325 | |||||
| D | 2026-02-19 | CRSP | Crispr Therapeutics AG | Kasinger James R. | GC, Secretary | S - Sale+OE | $52.58 | -2,112 | 85,115 | -2% | -$111,049 | |||||
| D | 2026-02-20 | KYMR | Kymera Therapeutics, Inc. | Esposito Pamela | Dir | S - Sale+OE | $87.31 | -2,500 | 0 | -100% | -$218,270 | |||||
2026-02-18 | LXEO | Lexeo Therapeutics, Inc. | Otero Jose Manuel | COO | S - Sale | $6.40 | -3,016 | 125,460 | -2% | -$19,294 | ||||||
2026-02-18 | LXEO | Lexeo Therapeutics, Inc. | Townsend Richard Nolan | CEO | S - Sale | $6.38 | -10,173 | 392,483 | -3% | -$64,924 | ||||||
| A | 2025-11-18 | LXEO | Lexeo Therapeutics, Inc. | Otero Jose Manuel | COO | S - Sale | $9.27 | -721 | 63,476 | -1% | -$6,684 | |||||
2026-02-18 | VYGR | Voyager Therapeutics, Inc. | Swartz Robin | COO, CBO | S - Sale | $3.44 | -3,882 | 206,196 | -2% | -$13,354 | ||||||
2026-02-18 | VYGR | Voyager Therapeutics, Inc. | Carter Todd Alfred | Chief Scientific Officer | S - Sale | $3.44 | -3,301 | 149,892 | -2% | -$11,355 | ||||||
2026-02-18 | VYGR | Voyager Therapeutics, Inc. | Sandrock Alfred | Pres, CEO | S - Sale | $3.41 | -11,732 | 498,257 | -2% | -$40,006 | ||||||
| D | 2026-02-19 | RXRX | Recursion Pharmaceuticals, Inc. | Gibson Christopher | Dir | S - Sale+OE | $3.46 | -40,000 | 906,556 | -4% | -$138,400 | |||||
2026-02-18 | RXRX | Recursion Pharmaceuticals, Inc. | Taylor Ben R | CFO | S - Sale | $3.08 | -13,426 | 1,195,349 | -1% | -$41,352 | ||||||
| DM | 2026-02-17 | EXEL | Exelixis, Inc. | Smith Julie | Dir | S - Sale+OE | $44.00 | -106,539 | 20,590 | -84% | -$4,687,346 | |||||
2026-02-19 | ACLX | Arcellx, Inc. | Gilson Michelle | CFO | S - Sale | $68.29 | -8,384 | 45,157 | -16% | -$572,568 | ||||||
2026-02-17 | NMRA | Neumora Therapeutics, Inc. | Aurora Daljit Singh | See Remarks | S - Sale | $3.56 | -6,165 | 82,770 | -7% | -$21,917 | ||||||
2026-02-17 | NMRA | Neumora Therapeutics, Inc. | Pinto Joshua | Pres | S - Sale | $3.54 | -5,967 | 209,950 | -3% | -$21,093 | ||||||
2026-02-17 | NMRA | Neumora Therapeutics, Inc. | Berns Paul L | See Remarks | S - Sale | $3.51 | -9,819 | 7,794,476 | 0% | -$34,459 | ||||||
2026-02-17 | NMRA | Neumora Therapeutics, Inc. | Milligan Michael Lee | See Remarks | S - Sale | $3.57 | -1,436 | 21,034 | -6% | -$5,119 | ||||||
| D | 2026-02-18 | IMCR | Immunocore Holdings Plc | Jallal Bahija | CEO | S - Sale+OE | $32.35 | -11,474 | 12,343 | -48% | -$371,184 | |||||
| D | 2026-02-18 | IMCR | Immunocore Holdings Plc | Goll John | SVP, FINANCE, CAO | S - Sale+OE | $32.35 | -698 | 653 | -52% | -$22,580 | |||||
| D | 2026-02-18 | IMCR | Immunocore Holdings Plc | St Leger Tina Amber | CHRO | S - Sale+OE | $32.35 | -1,000 | 1,119 | -47% | -$32,350 | |||||
| D | 2026-02-18 | IMCR | Immunocore Holdings Plc | Berman David M | HEAD OF R, D | S - Sale+OE | $32.35 | -5,965 | 5,859 | -50% | -$192,968 | |||||
| D | 2026-02-17 | TECH | Bio-Techne Corp | Herr Amy E. | Dir | S - Sale+OE | $59.11 | -1,976 | 2,880 | -41% | -$116,791 | |||||
| D | 2026-02-18 | DTIL | Precision Biosciences Inc | Amoroso Michael | Pres, CEO | S - Sale+OE | $3.84 | -20,559 | 243,392 | -8% | -$78,947 | |||||
| D | 2026-02-18 | DTIL | Precision Biosciences Inc | Kelly John Alexander | CFO | S - Sale+OE | $3.84 | -8,149 | 125,883 | -6% | -$31,292 | |||||
| D | 2026-02-18 | DTIL | Precision Biosciences Inc | Scimeca Dario | GC, Secretary | S - Sale+OE | $3.84 | -4,925 | 56,457 | -8% | -$18,912 | |||||
| D | 2026-02-18 | DTIL | Precision Biosciences Inc | Smith J. Jefferson | Chief Research Officer | S - Sale+OE | $3.84 | -4,925 | 129,857 | -4% | -$18,912 | |||||
2026-02-17 | SRRK | Scholar Rock Holding Corp | Marantz Jing L. | Chief Medical Officer | S - Sale | $46.53 | -4,157 | 126,012 | -3% | -$193,418 | ||||||
2026-02-17 | SRRK | Scholar Rock Holding Corp | Ho Junlin | GC | S - Sale | $46.53 | -9,580 | 241,545 | -4% | -$445,740 | ||||||
2026-02-17 | SRRK | Scholar Rock Holding Corp | Parlavecchio Caryn | CHRO | S - Sale | $46.53 | -9,035 | 169,087 | -5% | -$420,382 | ||||||
2026-02-17 | SRRK | Scholar Rock Holding Corp | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | S - Sale | $46.53 | -7,989 | 106,929 | -7% | -$371,714 | ||||||
2026-02-17 | TWST | Twist Bioscience Corp | Green Paula | SVP of HR | S - Sale | $52.40 | -39,404 | 126,041 | -24% | -$2,064,770 | ||||||
| D | 2026-02-17 | TWST | Twist Bioscience Corp | Finn Patrick John | Pres, COO | S - Sale+OE | $51.65 | -68,967 | 287,788 | -19% | -$3,562,417 | |||||
| D | 2026-02-18 | SLDB | Solid Biosciences Inc. | Cumbo Alexander | Pres, CEO | S - Sale+OE | $5.82 | -16,644 | 235,405 | -7% | -$96,923 | |||||
| D | 2026-02-18 | SLDB | Solid Biosciences Inc. | Hanrahan Jessie | Chief Regulatory Officer | S - Sale+OE | $5.82 | -4,134 | 74,318 | -5% | -$24,074 | |||||
| D | 2026-02-18 | SLDB | Solid Biosciences Inc. | Ganot Ilan | Dir | S - Sale+OE | $5.82 | -2,658 | 146,165 | -2% | -$15,478 | |||||
| D | 2026-02-18 | SLDB | Solid Biosciences Inc. | Herzich Paul | CTO | S - Sale+OE | $5.82 | -3,616 | 72,638 | -5% | -$21,057 | |||||
| D | 2026-02-18 | SLDB | Solid Biosciences Inc. | Howton David T | COO | S - Sale+OE | $5.82 | -7,469 | 105,077 | -7% | -$43,494 | |||||
| D | 2026-02-18 | SLDB | Solid Biosciences Inc. | Brooks Gabriel | Chief Medical Officer | S - Sale+OE | $5.82 | -0 | 89,466 | 0% | -$0 | |||||
| D | 2026-02-18 | SLDB | Solid Biosciences Inc. | Tan Kevin | CFO, Treasurer | S - Sale+OE | $5.82 | -5,404 | 99,422 | -5% | -$31,469 | |||||
| DM | 2026-02-17 | IVVD | Invivyd, Inc. | Allen Robert D. III | Chief Scientific Officer | S - Sale+OE | $1.56 | -37,581 | 114,487 | -25% | -$58,600 | |||||
| DM | 2026-02-17 | IVVD | Invivyd, Inc. | Green Julie | CHRO | S - Sale+OE | $1.56 | -40,627 | 107,717 | -27% | -$63,350 | |||||
| M | 2026-02-13 | EXEL | Exelixis, Inc. | Senner Christopher J. | EVP, CFO | S - Sale | $43.32 | -64,895 | 978,815 | -6% | -$2,810,998 | |||||
2026-02-17 | EXEL | Exelixis, Inc. | Haley Patrick J. | EVP, Commercial | S - Sale | $43.52 | -67,814 | 381,908 | -15% | -$2,950,941 | ||||||
2026-02-13 | EXEL | Exelixis, Inc. | Eckhardt Sue Gail | Dir | S - Sale | $43.79 | -3,856 | 17,524 | -18% | -$168,854 | ||||||
| DM | 2026-02-17 | IVVD | Invivyd, Inc. | Duke William E. | CFO | S - Sale+OE | $1.56 | -40,627 | 107,717 | -27% | -$63,350 | |||||
| D | 2026-02-13 | EXEL | Exelixis, Inc. | Oliver Bob | Dir | S - Sale+OE | $43.81 | -30,250 | 21,120 | -59% | -$1,325,339 | |||||
2026-02-18 | EXEL | Exelixis, Inc. | Hefti Brenda | SVP, GC | S - Sale | $44.01 | -18,669 | 102,039 | -15% | -$821,623 | ||||||
| DM | 2026-02-17 | IVVD | Invivyd, Inc. | Lee Timothy Edward | Chief Commercial Officer | S - Sale+OE | $1.56 | -40,627 | 117,717 | -26% | -$63,350 | |||||
| DM | 2026-02-17 | IVVD | Invivyd, Inc. | Andersen Jill | GC, Secretary | S - Sale+OE | $1.56 | -67,710 | 182,236 | -27% | -$105,581 | |||||
| D | 2026-02-17 | GILD | Gilead Sciences, Inc. | Mercier Johanna | Chief Comm, Corp Aff Officer | S - Sale+OE | $154.44 | -28,000 | 120,288 | -19% | -$4,324,228 | |||||
2026-02-17 | ACLX | Arcellx, Inc. | Gilson Michelle | CFO | S - Sale | $69.51 | -11,291 | 53,541 | -17% | -$784,783 | ||||||
2026-02-17 | GILD | Gilead Sciences, Inc. | Dickinson Andrew D | CFO | S - Sale | $154.43 | -3,000 | 167,779 | -2% | -$463,290 | ||||||
2026-02-13 | TWST | Twist Bioscience Corp | Chess Robert | Dir | S - Sale | $48.26 | -2,184 | 63,612 | -3% | -$105,402 | ||||||
2026-02-13 | VIR | Vir Biotechnology, Inc. | Sabatini Brent | SVP, Chief Accounting Officer | S - Sale | $7.79 | -1,530 | 47,872 | -3% | -$11,919 | ||||||
| D | 2026-02-17 | ADMA | Adma Biologics, Inc. | Grossman Adam S | Pres, CEO | S - Sale+OE | $16.08 | -21,000 | 4,008,762 | -1% | -$337,680 | |||||
| D | 2026-02-12 | BIIB | Biogen Inc. | Murphy Nicole | Head of Pharm Ops, Tech | P - Purchase | $195.04 | +3 | 19,611 | 0% | +$585 | |||||
2025-12-18 | KLRS | Kalaris Therapeutics, Inc. | Akkaraju Srinivas | Dir, 10% | P - Purchase | $10.42 | +479,847 | 12,948,081 | +4% | +$5,000,006 | ||||||
2026-02-17 | AURA | Aura Biosciences, Inc. | Kilroy Conor | See Remarks | S - Sale | $5.05 | -12,079 | 167,234 | -7% | -$60,999 | ||||||
2026-02-17 | AURA | Aura Biosciences, Inc. | Plavsic Mark | CTO | S - Sale | $5.05 | -15,890 | 181,397 | -8% | -$80,245 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |